Report Detail
Genome Editing Global Market - Forecast to 2022
- RnM3925054 |
- 12 March, 2020 |
- Global |
- 274 Pages |
- IQ4I Research & Consultancy |
- Biotechnology
Ever since the establishment of the genetic basis of life, researchers have tried to manipulate genes in plants and animals to improve traits. There has been a continuous evolution of gene modification technique starting from restriction endonucleases, transgenic breeding, RNAi technologies to the current engineered endonucleases. Over the last several decades, technologies for identification, isolation, sequencing, replication and integration of desired genes in target organisms have transformed tremendously and emerged as one of the exciting and significant areas of scientific endeavour.
The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc. Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software. Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.
This report studies the genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at high double digit CAGR to reach $2,669.9 million by 2022. Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America dominated the genome editing market with the largest share which is driven by factors such as increasing awareness of technology, proximity of companies, and early adoption of latest treatments. The Asian market is expected to occupy second place due increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed regulatory environment. The European market is expected to be third largest market, growing at a lower rate mainly due to the stringent regulatory environment and slow growth due to the economic crisis.
The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).
1 EXECUTIVE SUMMARY 21
2 INTRODUCTION 26
- 2.1 KEY TAKEAWAYS 26
- 2.2 REPORT DESCRIPTION 26
- 2.3 MARKETS COVERED 28
- 2.4 STAKEHOLDERS 29
- 2.5 RESEARCH METHODOLOGY 29
- 2.5.1 MARKET SIZE ESTIMATION 31
- 2.5.2 MARKET CRACKDOWN & DATA TRIANGULATION 33
- 2.5.3 SECONDARY SOURCES 34
- 2.5.4 PRIMARY SOURCES 34
- 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 35
- 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 35
- 2.5.7 ASSUMPTIONS 36
3 MARKET OVERVIEW 37
- 3.1 INTRODUCTION 37
- 3.2 MARKET SEGMENTATION 38
- 3.3 FACTORS INFLUENCING MARKET 40
- 3.4 MARKET DYNAMICS 41
- 3.4.1 DRIVERS AND OPPORTUNITIES 41
- 3.4.1.1 Increased R&D expenditure and growth of biotechnology and pharmaceutical industries. 41
- 3.4.1.2 Investments from both public and private sectors for gene-editing technology 41
- 3.4.1.3 Technological advancements in sequencing and gene editing technologies 42
- 3.4.1.4 Non-transgenic breeding technologies and gene-edited plants not
labelled as GMO in many countries 43
- 3.4.1.5 Improvement in drug discovery process 43
- 3.4.1.6 Varied applications in drug discovery and development, plant engineering, improvement in animal traits, therapeutics 44
- 3.4.1.7 Precision medicine and new therapeutics for genetic and other disorders 45
- 3.4.1 DRIVERS AND OPPORTUNITIES 41
- 3.4.2 RESTRAINTS AND THREATS 45
- 3.4.2.1 Stringent regulatory frameworks 45
- 3.4.2.2 Ethical issues concerning editing human embryo and adverse public perception 46
- 3.4.2.3 Unavailability of gene-editing based therapeutic product in the market
and less geographic penetration due to uncertain regulations 47
- 3.4.2.4 Patent dispute associated with CRISPR/CAS 47
- 3.4.2.5 Off-target effects of CRISPR/CAS9 genome editing technology 48
- 3.5.1 THREAT OF NEW ENTRANTS 50
- 3.5.2 THREAT OF SUBSTITUTES 50
- 3.5.3 BARGAINING POWER OF SUPPLIERS 51
- 3.5.4 BARGAINING POWER OF BUYERS 52
- 3.5.5 RIVALRY AMONG EXISTING COMPETITORS 52
- 3.6.1 NORTH AMERICA 54
- 3.6.2 EUROPE 55
- 3.6.3 CHINA 56
- 3.6.4 JAPAN 57
- 3.6.5 INDIA 57
- 3.6.6 LATIN AMERICA 57
4 GENOME EDITING GLOBAL MARKET, BY TECHNOLOGY 77
- 4.1 INTRODUCTION 77
- 4.2 ZINC FINGER NUCLEASE (ZFN) 79
- 4.3 TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES (TALEN) 82
- 4.4 CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC
REPEATS (CRISPR/CAS9) 84
- 4.4.1 WT CRISPR/CAS9 88
- 4.4.2 CRISPR/CAS9 NICKASE 88
- 4.4.3 CRISPR DCAS9 89
- 4.5.1 RECOMBINANT ADENO-ASSOCIATED VIRUS (R AAV) 90
- 4.5.2 PIGGYBAC TRANSPOSASE AND SLEEPING BEAUTY TRANSPOSON 90
- 4.5.3 ARCUS (HOMING ENDONUCLEASE) AND MEGATAL 91
- 4.5.4 TARGATT AND RAPID TRAIT DEVELOPMENT SYSTEM (RTDS) 91
5 GENOME EDITING GLOBAL MARKET, BY APPLICATION 93
- 5.1 INTRODUCTION 93
- 5.2 BASIC RESEARCH 96
- 5.2.1 TRANSCRIPTION ACTIVATION/REPRESSION 96
- 5.2.2 GENOMIC SCREENING 97
- 5.2.3 GENOMIC VISUALIZATION 97
- 5.3 PLANT BIOTECHNOLOGY/AGRICULTURE 99
- 5.4 ANIMAL BIOTECHNOLOGY 101
- 5.4.1 ANIMAL HEALTH 101
- 5.4.2 LIVESTOCK 101
- 5.4.3 OTHER 101
- 5.5 DRUG DISCOVERY AND DEVELOPMENT 104
- 5.5.1 PRE-CLINICAL 105
- 5.5.2 CLINICAL 107
6 GENOME EDITING GLOBAL MARKET, BY PRODUCTS AND SERVICES 111
- 6.1 INTRODUCTION 111
- 6.2 REAGENTS, ENZYMES AND CONSUMABLES 114
- 6.2.1 GENOME EDITING TOOLS AND KITS 114
- 6.2.2 DELIVERY TOOLS 115
- 6.2.3 OTHER REAGENTS, ENZYMES AND CONSUMABLES 115
- 6.3 CELL LINES AND ANIMAL MODELS 117
- 6.4 GENOME EDITING SERVICES 119
- 6.5 INSTRUMENTS 121
- 6.6 SOFTWARE 123
7 GENOME EDITING GLOBAL MARKET, BY END USERS 125
- 7.1 INTRODUCTION 125
- 7.2 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 128
- 7.3 PLANT BIOTECHNOLOGY COMPANIES 130
- 7.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 132
- 7.5 OTHERS 134
- 7.5.1 ANIMAL BIOTECHNOLOGY 134
- 7.5.2 CONTRACT RESEARCH ORGANIZATIONS (CRO) 134
8 GENOME EDITING GLOBAL MARKET, BY REGION 136
- 8.1 INTRODUCTION 136
- 8.2 NORTH AMERICA 139
- 8.2.1 U.S. 139
- 8.3 EUROPE 149
- 8.4 ASIA-PACIFIC 159
- 8.4.1 CHINA 159
- 8.4.2 JAPAN 160
- 8.4.3 INDIA 160
- 8.5 REST OF THE WORLD (ROW) 170
- 8.5.1 LATIN AMERICA 170
- 8.5.2 MIDDLE EAST 170
9 COMPETITIVE LANDSCAPE 180
- 9.1 INTRODUCTION 180
- 9.1.1 LICENSING AGREEMENT AND OTHERS AS A MAJOR GROWTH
STRATEGY OF MARKET PLAYERS 181
- 9.2 LICENSING AGREEMENT 181
- 9.3 OTHER DEVELOPMENTS 186
- 9.4 AGREEMENT/COLLABORATION/PARTNERSHIP/JOINT VENTURE 189
- 9.5 APPROVAL 193
- 9.6 NEW PRODUCT LAUNCH 195
- 9.7 ACQUISITIONS 196
10 MAJOR COMPANIES 197
- 10.1 APPLIED STEMCELL INC. 197
- 10.1.1 OVERVIEW 197
- 10.1.2 FINANCIALS 197
- 10.1.3 PRODUCT PORTFOLIO 198
- 10.1.4 KEY DEVELOPMENTS 202
- 10.1.5 BUSINESS STRATEGY 203
- 10.1.6 SWOT ANALYSIS 204
- 10.2 CELLECTIS S.A. 205
- 10.2.1 OVERVIEW 205
- 10.2.2 FINANCIALS 206
- 10.2.3 PRODUCT PORTFOLIO 208
- 10.2.4 KEY DEVELOPMENTS 210
- 10.2.5 BUSINESS STRATEGY 212
- 10.2.6 SWOT ANALYSIS 213
- 10.3 GENSCRIPT BIOTECH CORPORATION 214
- 10.3.1 OVERVIEW 214
- 10.3.2 FINANCIALS 215
- 10.3.3 PRODUCT PORTFOLIO 218
- 10.3.4 KEY DEVELOPMENTS 220
- 10.3.5 BUSINESS STRATEGY 221
- 10.3.6 SWOT ANALYSIS 222
- 10.4 HORIZON DISCOVERY GROUP, PLC 223
- 10.4.1 OVERVIEW 223
- 10.4.2 FINANCIALS 224
- 10.4.3 PRODUCT PORTFOLIO 226
- 10.4.4 KEY DEVELOPMENTS 229
- 10.4.5 BUSINESS STRATEGY 231
- 10.4.6 SWOT ANALYSIS 232
- 10.5 MERCK KGAA 233
- 10.5.1 OVERVIEW 233
- 10.5.2 FINANCIALS 234
- 10.5.3 PRODUCT PORTFOLIO 236
- 10.5.4 KEY DEVELOPMENTS 238
- 10.5.5 BUSINESS STRATEGY 239
- 10.5.6 SWOT ANALYSIS 240
- 10.6 ORIGENE TECHNOLOGIES, INC. 241
- 10.6.1 OVERVIEW 241
- 10.6.2 FINANCIALS 241
- 10.6.3 PRODUCT PORTFOLIO 242
- 10.6.4 KEY DEVELOPMENTS 243
- 10.6.5 BUSINESS STRATEGY 243
- 10.6.6 SWOT ANALYSIS 244
- 10.7 SANGAMO BIOSCIENCES 245
- 10.7.1 OVERVIEW 245
- 10.7.2 FINANCIALS 246
- 10.7.3 PRODUCT PORTFOLIO 248
- 10.7.4 KEY DEVELOPMENTS 249
- 10.7.5 BUSINESS STRATEGY 251
- 10.7.6 SWOT ANALYSIS 252
- 10.8 SYSTEM BIOSCIENCES 253
- 10.8.1 OVERVIEW 253
- 10.8.2 FINANCIALS 253
- 10.8.3 PRODUCT PORTFOLIO 253
- 10.8.4 KEY DEVELOPMENTS 257
- 10.8.5 BUSINESS STRATEGY 258
- 10.8.6 SWOT ANALYSIS 258
- 10.9 THERMO FISHER SCIENTIFIC INC. 259
- 10.9.1 OVERVIEW 259
- 10.9.2 FINANCIALS 260
- 10.9.3 PRODUCT PORTFOLIO 263
- 10.9.4 KEY DEVELOPMENTS 265
- 10.9.5 BUSINESS STRATEGY 266
- 10.9.6 SWOT ANALYSIS 267
- 10.10 TRANSPOSAGEN 268
- 10.10.1 OVERVIEW 268
- 10.10.2 FINANCIALS 268
- 10.10.3 PRODUCT PORTFOLIO 269
- 10.10.4 KEY DEVELOPMENTS 271
- 10.10.5 BUSINESS STRATEGY 272
Summary:
Get latest Market Research Reports on Genome Editing. Industry analysis & Market Report on Genome Editing is a syndicated market report, published as Genome Editing Global Market - Forecast to 2022. It is complete Research Study and Industry Analysis of Genome Editing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
